User:Mr. Ibrahem/Pertuzumab

Pertuzumab, sold under the brand name Perjeta, is a medication used to treat breast cancer. Specifically it is used for HER2-positive cases in combination with trastuzumab and possibly docetaxel. It is given by gradual injection into a vein.

Common side effects include diarrhea, hair loss, low neutrophils, nausea, tiredness, rash, and peripheral nerve problems. Other side effects may include heart failure, infusion reaction, and anaphylaxis. Use during pregnancy may harm the baby. It is a monoclonal antibody which attaches to HER2 on cells and blocks signals that cause the cancer to grow.

Pertuzumab was approved for medical use in the United States in 2012 and Europe in 2013. In the United Kingdom it costs the NHS about £2,400 per 420 mg as of 2021. This amount in the United States costs about US$5,800.